FDA Investigating Deaths Following Injections of Zyprexa | CT Law Firm
Koskoff Koskoff & Bieder, PC
p: 203-583-8634
Navigation Menu

FDA Investigating Deaths Following Injections of Zyprexa

The FDA announced this week that it is investigating the deaths of two patients who died several days after receiving intramuscular injections of the long-acting antipsychotic drug Zyprexa Relprevv (olanzapine pamoate). According to the investigation, both patients received appropriate doses of the drug, and both were found to have "very high olanzapine blood levels after death." High doses of olanzapine can cause delirium, cardiopulmonary arrest, cardiac arrhythmias, and impaired levels of consciousness ranging from sedation to coma. The FDA has not yet determined if the drug is the cause of the fatalities. Zyprexa Relprevv is used for treating patients with schizophrenia.